The ISAR leadership underwent the periodic yearly renewal at the end of the virtual ICAR 2021,when Pei-Yong Shi and Joana Rocha-Pereira completed their two years of service as members of the Board of Directors. We would like to thank them very much for their service as members of the board in such a challenging times, and we are all look forward to their continuing involvement with the society.
ISAR was honored to have Pei-Yong as a member of the board since 2019. He is the John Sealy Distinguished Chair in Innovations in Molecular Biology at University of Texas Medical Branch (UTMB). He works on RNA virus, drug discovery, and vaccine research. His unique expertise in public health laboratory (York State Department of Health), pharmaceutical companies (Novartis and Bristol-Myers Squibb), and academia (UTMB and Yale) allows him to work on both basic and translational research. He has published >320 peer-reviewed papers. Besides academic excellence, he also has a stellar track record of senior leadership role at major pharmaceutical companies, including as the Executive Director at Novartis Institute for Tropical Diseases where he set up antiviral strategies and executed drug discovery and development. Many of his technologies have been licensed to leading pharmaceutical companies for countermeasure development. A recent example is his reporter neutralization assay that has enabled the rapid development of Pfizer’s COVID-19 vaccine, the first vaccine with 95% efficacy in humans.
Pei-Yong was elected to the Board of Directors in 2019. During his tenure, he was very active supporting all Society’s activities all the while continuing his most valuable work on antiviral and vaccine research and development. Please join us in thanking Pei-Yong for his excellent service to the society.
15 April 2021
About ISAR NEWS
The official newsletter of the International Society for Antiviral Research
© Publications workgroup (Communications & Outreach Committee) and Luis M Schang, Editor